Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now

Get ready, bargain shoppers. Foamix (FOMX) has plummeted 27% since the beginning of the year and it looks like the stock received more …

Oppenheimer Initiates Outperform On Foamix Pharmaceuticals; Sees 163% Upside

In a research report issued today, Oppenheimer analyst Akiva Felt initiated coverage with an Outperform rating on Foamix Pharmaceuticals (NASDAQ:FOMX) and a $15 price target, which represents …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts